keyword
MENU ▼
Read by QxMD icon Read
search

Progression-free survival

keyword
https://www.readbyqxmd.com/read/28335429/the-adverse-effect-of-hypertension-in-the-treatment-of-thyroid-cancer-with-multi-kinase-inhibitors
#1
REVIEW
Ole Vincent Ancker, Markus Wehland, Johann Bauer, Manfred Infanger, Daniela Grimm
The treatment of thyroid cancer has promising prospects, mostly through the use of surgical or radioactive iodine therapy. However, some thyroid cancers, such as progressive radioactive iodine-refractory differentiated thyroid carcinoma, are not remediable with conventional types of treatment. In these cases, a treatment regimen with multi-kinase inhibitors is advisable. Unfortunately, clinical trials have shown a large number of patients, treated with multi-kinase inhibitors, being adversely affected by hypertension...
March 14, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28334974/efficacy-and-safety-of-sequential-use-of-everolimus-in-japanese-patients-with-advanced-renal-cell-carcinoma-after-failure-of-first-line-treatment-with-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitor-a-multicenter-phase-ii-clinical-trial
#2
Masafumi Oyama, Takayuki Sugiyama, Masahiro Nozawa, Kiyohide Fujimoto, Takeshi Kishida, Go Kimura, Noriaki Tokuda, Shiro Hinotsu, Kojiro Shimozuma, Hideyuki Akaza, Seiichiro Ozono
Objective: Many studies have shown the efficacy of everolimus after pretreatment with vascular endothelial growth factor receptor-tyrosine kinase inhibitors. We investigated the efficacy and safety of everolimus as a second-line treatment after the failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy in Japanese patients with advanced renal cell carcinoma. Methods: This was an open-label, multicenter, phase II trial conducted in Japan through the central registration system...
March 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28334948/a-phase-i-ii-trial-of-continuous-hepatic-intra-arterial-infusion-of-5-fluorouracil-mitoxantrone-and-cisplatin-for-advanced-hepatocellular-carcinoma
#3
Masafumi Ikeda, Takuji Okusaka, Yozo Sato, Junji Furuse, Shuichi Mitsunaga, Hideki Ueno, Chigusa Morizane, Yoshitaka Inaba, Tatsushi Kobayashi, Yasuaki Arai
Background: The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC). Methods: Forty-five patients with advanced HCC were enrolled. The therapy consisted of continuous intra-arterial infusion of 5-fluorouracil from Day 1 through Day 5, and intra-arterial administration of mitoxantrone and cisplatin on Day 1 [5-fluorouracil/mitoxantrone/cisplatin (mg/m2): Level 1; 400/4/60, Level 2; 400/6/60, Level 3; 500/6/60]...
March 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28334837/clinical-outcome-of-definitive-radiation-therapy-for-superficial-esophageal-cancer
#4
Yutaro Koide, Takeshi Kodaira, Hiroyuki Tachibana, Natsuo Tomita, Chiyoko Makita, Makoto Itoh, Tetsuya Abe, Kei Muro, Masahiro Tajika, Yasumasa Niwa, Yoshiyuki Itoh, Shinji Naganawa
Objective: To analyze the clinical outcome of concurrent chemoradiotherapy in superficial esophageal cancer patients. Methods: We retrospectively analyzed data for 123 patients with superficial esophageal cancer who received external beam radiotherapy without intracavitary brachytherapy plus systemic chemotherapy during 1998-2015. Elective nodal irradiation was not performed. The dosage to planning treatment volume was 60 Gy in 30 fractions. The main outcome measure was overall survival...
February 23, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28334788/impact-of-divergent-differentiation-in-urothelial-carcinoma-on-oncological-outcome-in-patients-with-t1-high-grade-bladder-cancer
#5
Nakanori Fujii, Yoshinobu Hoshii, Hiroshi Hirata, Junichi Mori, Kosuke Shimizu, Keita Kobayashi, Yoshihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroaki Matsumoto, Kazuhiro Nagao, Hideyasu Matsuyama
Objective: T1 high-grade bladder cancer has a poor prognosis compared with other non-muscle-invasive bladder cancers. We investigated the clinical outcomes among patients with T1 high-grade bladder cancer to identify factors related to cancer recurrence and disease progression. Methods: We retrospectively reviewed the data of 148 patients who were diagnosed with T1 high-grade bladder cancer by transurethral resection from January 2001 to February 2015 at our institution...
March 8, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28334439/a-phase-2-trial-of-dasatinib-in-patients-with-locally-advanced-or-stage-iv-mucosal-acral-or-vulvovaginal-melanoma-a-trial-of-the-ecog-acrin-cancer-research-group-e2607
#6
Kevin Kalinsky, Sandra Lee, Krista M Rubin, Donald P Lawrence, Anthony J Iafrarte, Darell R Borger, Kim A Margolin, Mario M Leitao, Ahmad A Tarhini, Henry B Koon, Andrew L Pecora, Anthony J Jaslowski, Gary I Cohen, Timothy M Kuzel, Christopher D Lao, John M Kirkwood
BACKGROUND: KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison with other tyrosine kinase inhibitors against cells with the most common KIT mutation, exon 11(L576P) . The ECOG-ACRIN E2607 trial assessed dasatinib in patients with these melanoma subtypes. METHODS: Patients received 70 mg of oral dasatinib twice daily...
March 23, 2017: Cancer
https://www.readbyqxmd.com/read/28334430/radiofrequency-ablation-using-a-10-mm-target-margin-for-small-hepatocellular-carcinoma-in-patients-with-liver-cirrhosis-a-prospective-randomized-trial
#7
Mingheng Liao, Xiaofei Zhong, Jingyi Zhang, Yangyang Liu, Zexin Zhu, Hong Wu, Yong Zeng, Jiwei Huang
BACKGROUND AND OBJECTIVES: To compare 3-year clinical outcomes of radiofrequency ablation (RFA) targeting 5- or 10-mm margins for small hepatocellular carcinomas (HCCs) in cirrhotic patients. METHODS: In total, 96 cirrhotic patients with a small solitary HCC (diameter ≤3 cm) were included in this prospective trial (ChiCTRTRC-10000954). Patients were stratified by Child-Pugh class and randomly allocated into groups targeting either wide margins (≥10 mm, WM) or narrow margins (≥5 mm but <10 mm, NM)...
March 23, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28334047/clinical-validation-of-chemotherapy-predictors-developed-on-global-microrna-expression-in-the-nci60-cell-line-panel-tested-in-ovarian-cancer
#8
Kira Philipsen Prahm, Claus Høgdall, Mona Aarenstrup Karlsen, Ib Jarle Christensen, Guy Wayne Novotny, Steen Knudsen, Anker Hansen, Peter Buhl Jensen, Thomas Jensen, Mansoor Raza Mirza, Anne Weng Ekmann-Gade, Lotte Nedergaard, Estrid Høgdall
OBJECTIVE: Ovarian cancer is the leading cause of death among gynecologic malignancies. This is partly due to a non-durable response to chemotherapy. Prediction of resistance to chemotherapy could be a key role in more personalized treatment. In the current study we aimed to examine if microRNA based predictors could predict resistance to chemotherapy in ovarian cancer, and to investigate if the predictors could be prognostic factors for progression free and overall survival. METHODS: Predictors of chemotherapy-resistance were developed based on correlation between miRNA expression and differences in measured growth inhibition in a variety of human cancer cell lines in the presence of Carboplatin, Paclitaxel and Docetaxel...
2017: PloS One
https://www.readbyqxmd.com/read/28333951/prognostic-value-of-plasma-egfr-ctdna-in-nsclc-patients-treated-with-egfr-tkis
#9
Chengjuan Zhang, Bing Wei, Peng Li, Ke Yang, Zhizhong Wang, Jie Ma, Yongjun Guo
OBJECTIVE: Epidermal growth factor receptor (EGFR) specific mutations have been known to improve survival of patients with non-small-cell lung carcinoma (NSCLC). However, whether there are any changes of EGFR mutations after targeted therapy and its clinical significance is unclear. This study was to identify the status of EGFR mutations after targeted therapy and predict the prognostic significance for NSCLC patients. METHODS: A total of forty-five (45) NSCLC patients who received EGFR-TKI therapy were enrolled...
2017: PloS One
https://www.readbyqxmd.com/read/28333846/prognostic-value-of-fluorine-18-fluorodeoxyglucose-uptake-of-bone-marrow-on-positron-emission-tomography-computed-tomography-for-prediction-of-disease-progression-in-cervical-cancer
#10
Jeong Won Lee, Seob Jeon, Seong Taek Mun, Sang Mi Lee
OBJECTIVE: This study aimed to evaluate the prognostic value of fluorine-18 fluorodeoxyglucose (FDG) uptake of bone marrow (BM) on positron emission tomography (PET)/computed tomography in patients with uterine cervical cancer. METHODS: One hundred forty-five patients with cervical cancer who underwent staging FDG PET/computed tomography and subsequent surgical resection or chemoradiotherapy were retrospectively enrolled in the study. Mean BM FDG uptake (BM standardized uptake value [SUV]) and BM-to-liver uptake ratio of FDG uptake (BLR) were measured...
March 23, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28333566/is-change-in-hemoglobin-level-a-predictive-biomarker-of-tyrosine-kinase-efficacy-in-metastatic-renal-cell-carcinoma-a-turkish-oncology-group-study
#11
Cemil Bilir, İbrahim Yıldız, Ahmet Bilici, Mahmut Ucar, Veli Berk, Yaşar Yıldız, Ozan Yazıcı, Gökşen İnanç İmamoğlu, Nuri Karadurmuş, Kezban Nur Pilancı, Erkan Arpacı, Özgür Tanrıverdi, Ebru Karcı, Süleyman Temiz, Erdinc Nayır, Esin Oktay, Pınar Dal, İbrahim Petekkaya, Ceyhun Varım, Hakan Cinemre
BACKGROUND: There are insufficient predictive markers for renal cell carcinoma (RCC). METHODS: A total of 308 metastatic RCC patients were analyzed retrospectively. RESULTS: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35 months (p < .001) and 21.0 versus 11.36 months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i...
March 23, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28332983/radical-cystectomy-compared-to-combined-modality-treatment-for-muscle-invasive-bladder-cancer-a-systematic-review-and-meta-analysis
#12
Vishal Vashistha, Hanzhang Wang, Andrew Mazzone, Michael A Liss, Robert S Svatek, Mary Schleicher, Dharam Kaushik
PURPOSE: To perform a comprehensive comparison of overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), and treatment-related complications between radical cystectomy (RC) and combined modality treatment (CMT-radiation therapy, concurrent chemotherapy, and maximal transurethral resection of bladder tumor) in the setting of muscle-invasive bladder cancer. METHODS AND MATERIALS: We searched 7 databases (PubMed, Scopus, EMBASE, Proquest, CINAHL, and ClinicalTrials...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28332624/effects-of-icotinib-with-and-without-radiation-therapy-on-patients-with-egfr-mutant-non-small-cell-lung-cancer-and-brain-metastases
#13
Yun Fan, Yanjun Xu, Lei Gong, Luo Fang, Hongyang Lu, Jing Qin, Na Han, Fajun Xie, Guoqin Qiu, Zhiyu Huang
EGFR-TKIs and radiation therapy (RT) are the principal treatment for patients with brain metastases (BM) and EGFR mutant NSCLC. However, the optimal use of brain RT for patients with asymptomatic BM remains undefined. A total of 152 patients were identified. 58 patients were excluded. Of the remaining 97 patients, 56 patients received upfront RT followed by icotinib, including WBRT or SRS. 41 patients received icotinib therapy alone. The mOS from diagnosis of BM was 27.0 months for the whole cohort (95% CI, 23...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28332580/clinical-impact-of-single-nucleotide-polymorphism-in-pd-l1-on-response-to-nivolumab-for-advanced-non-small-cell-lung-cancer-patients
#14
Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim
This study was intended to determine the efficacy of nivolumab, we evaluated treatment response with respect to PD-1/PD-L1 SNPs among patients with NSCLC. A total of 50 patients with NSCLC were treated with nivolumab and were also evaluated for PD-1/PD-L1 single nucleotide polymorphisms (SNPs) from plasma DNA. We investigated the association among PD-1/PD-L1 SNPs, objective response rate (ORR) and progression-free survival (PFS). Two of seven SNPs studied showed association with ORR and PFS, with maximum evidence at the marker rs2282055...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28332433/the-cost-effectiveness-of-alectinib-in-anaplastic-lymphoma-kinase-positive-alk-advanced-nsclc-previously-treated-with-crizotinib
#15
J J Carlson, W Canestaro, A Ravelo, W Wong
Introduction Anaplastic lymphoma kinase (ALK) targeting drugs provide an important option for advanced non-small cell lung cancer patients with this distinct tumor type; however, there is considerable uncertainty as to which drug provides the optimal value after crizotinib treatment. This study estimated the cost-utility of alectinib vs ceritinib from a US payer perspective. Methods A cost-utility model was developed using partition survival methods and three health states: progression-free (PF), post-progression (PP), and death...
March 23, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28332314/the-mitochondrial-hinge-protein-uqcrh-is-a-novel-prognostic-factor-for-hepatocellular-carcinoma
#16
Eun-Ran Park, Sang-Bum Kim, Jee-San Lee, Yang-Hyun Kim, Dong-Hyoung Lee, Eung-Ho Cho, Sun-Hoo Park, Chul Ju Han, Bu-Yeo Kim, Dong Wook Choi, Young Do Yoo, Ami Yu, Jae Won Lee, Ja June Jang, Young Nyun Park, Kyung-Suk Suh, Kee-Ho Lee
Alterations in mitochondrial respiration contribute to the development and progression of cancer via abnormal biogenesis, including generation of reactive oxygen species. Ubiquinol-cytochrome c reductase hinge protein (UQCRH) consists of the cytochrome bc1 complex serving respiration in mitochondria. In the present study, we analyzed UQCRH abnormalities in hepatocellular carcinoma (HCC) and its association with clinical outcomes of patients. UQCRH expression in HCC was determined via semiquantitative and quantitative real-time reverse transcriptase polymerase chain reaction of 96 surgically resected HCC tissues positive for hepatitis B virus surface antigen...
March 23, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28332083/phase-iii-soft-tissue-sarcoma-trials-success-or-failure
#17
REVIEW
Alexander T J Lee, Seth M Pollack, Paul Huang, Robin L Jones
Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II data that guided the selection of sensitive STS diagnoses, enabling the demonstration of benefit in certain subtypes. A number of other phase III trials reported in the last 18 months have seemingly fit into a recurrent pattern of failure-promising efficacy signals in earlier phase studies being lost in the survival follow-up of large, highly heterogeneous cohorts...
March 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28331985/one-month-assessment-of-renal-cell-carcinoma-treated-by-everolimus-using-fdg-pet-ct-predicts-progression-free-and-overall-survival
#18
Hiroki Ito, Keiichi Kondo, Takashi Kawahara, Tomohiro Kaneta, Ukihide Tateishi, Daiki Ueno, Kazuhiro Namura, Kazuki Kobayashi, Yasuhide Miyoshi, Yasushi Yumura, Kazuhide Makiyama, Narihiko Hayashi, Hisashi Hasumi, Kimito Osaka, Yumiko Yokomizo, Jun-Ichi Teranishi, Yusuke Hattori, Tomio Inoue, Hiroji Uemura, Masahiro Yao, Noboru Nakaigawa
PURPOSE: We evaluated (18)F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) results as outcome predictors for patients with metastatic renal cell carcinoma (RCC) treated by everolimus (EVL), an inhibitor of mammalian target of rapamycin. METHODS: We retrospectively reviewed 30 patients who were treated with EVL for metastatic RCC between May 2010 and March 2015, by evaluating their FDG PET/CT result before and 1 month after starting EVL treatment...
March 22, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28331819/clinical-outcomes-of-cyberknife-stereotactic-radiosurgery-for-elderly-patients-with-presumed-primary-stage-i-lung-cancer
#19
Zhen Wang, Ao-Mei Li, Jie Gao, Jing Li, Bing Li, Percy Lee, Charles B Simone, Yong Song, Xi-Xu Zhu
BACKGROUND: In certain situations, especially in the elderly patient population, a tissue diagnosis of a suspected pulmonary neoplasm is not feasible. Often, a definitive treatment such as stereotactic body radiosurgery is recommended, rather than active surveillance. The aim of this study is to evaluate the efficacy and tolerability of stereotactic body radiotherapy (SBRT) for elderly patients with presumed primary stage I lung cancer without pathological tissue confirmation. METHODS: We performed a retrospective analysis of 25 elderly patients (≥75 years) with presumed primary stage I lung cancer treated with SBRT from 2009-2015...
February 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28331615/nuclear-irf-1-expression-as-a-mechanism-to-assess-capability-to-express-pd-l1-and-response-to-pd-1-therapy-in-metastatic-melanoma
#20
James W Smithy, Lauren M Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M Neumeister, Mario Sznol, Harriet M Kluger, David L Rimm
BACKGROUND: Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (PD-L1), highlighting the need for a more sensitive biomarker. We hypothesize that capacity to express PD-L1, as assessed by an assay for a PD-L1 transcription factor, interferon regulatory factor 1 (IRF-1), may better distinguish patients likely to benefit from anti-PD-1 immunotherapy...
2017: Journal for Immunotherapy of Cancer
keyword
keyword
119233
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"